for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Blueprint Medicines Corp

BPMC.O

Latest Trade

103.34USD

Change

0.00(-0.00%)

Volume

794,588

Today's Range

98.89

 - 

103.44

52 Week Range

43.29

 - 

108.50

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
103.34
Open
99.07
Volume
794,588
3M AVG Volume
9.75
Today's High
103.44
Today's Low
98.89
52 Week High
108.50
52 Week Low
43.29
Shares Out (MIL)
55.73
Market Cap (MIL)
5,503.97
Forward P/E
18.65
Dividend (Yield %)
--

Next Event

Q4 2020 Blueprint Medicines Corp Earnings Release

Latest Developments

More

Blueprint Medicines Reports Q3 Earnings Per Share $11.16

Blueprint Medicines Announces European Commission Approval Of Ayvakyt® (Avapritinib) For The Treatment Of Adults With Unresectable Or Metastatic Pdgfra D842v Mutant Gastrointestinal Stromal Tumo

Blueprint Medicines Announces Positive Top-Line Results From Explorer And Pathfinder Trials Of Ayvakit

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Blueprint Medicines Corp

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease. Its drug candidate, BLU-285, targets KIT, including Exon 17 mutations, and targets PDGFRa, including the D842V mutation. These mutations activate receptor tyrosine kinases that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors (GIST), and systemic mastocytosis (SM). Its drug candidate BLU-554 targets FGFR4, a kinase that is activated in a defined subset of patients with hepatocellular carcinoma (HCC), the common type of liver cancer. It is engaged in developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is activated by mutations or translocations.

Industry

Biotechnology & Drugs

Contact Info

45 Sidney St

CAMBRIDGE, MA

02139-4133

United States

+1.617.3747580

http://www.blueprintmedicines.com/

Executive Leadership

Daniel S. Lynch

Independent Chairman of the Board

Fouad Namouni

President, Research & Development

Jeffrey W. Albers

Chief Executive Officer, Director

Michael Landsittel

Chief Financial Officer

Kathryn Haviland

Chief Operating Officer

Key Stats

1.87 mean rating - 15 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.1K

2020(E)

0.8K
EPS (USD)

2017

-3.920

2018

-5.390

2019

-7.270

2020(E)

5.297
Price To Earnings (TTM)
18.18
Price To Sales (TTM)
6.79
Price To Book (MRQ)
4.15
Price To Cash Flow (TTM)
16.20
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
31.86
Return on Equity (TTM)
29.02

Latest News

Latest News

Roche, Blueprint lung cancer drug wins FDA approval

Roche Holding AG on Friday said a therapy it co-developed with Cambridge-based Blueprint Medicines Corp was approved by the U.S. health regulator for the treatment of patients with a type of non-small cell lung cancer (NSCLC).

Roche gene testing key to $1.7 billion deal for Blueprint cancer drug

Roche <ROG.S> has struck a $1.7 billion cancer drug pact with Blueprint Medicines <BPMC.O>, it said on Tuesday, as advances in genetic testing for rare mutations drive lucrative deals for expensive treatments.

BRIEF-Blueprint Medicines Announces Submission Of New Drug Application To FDA For Pralsetinib

* BLUEPRINT MEDICINES ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION TO FDA FOR PRALSETINIB FOR THE TREATMENT OF ADVANCED RET MUTANT AND RET FUSION-POSITIVE THYROID CANCERS Source text for Eikon: Further company coverage:

BRIEF-Blueprint Medicines Highlights Durable Clinical Activity And Well-Tolerated Safety Profile Of Pralsetinib Across Broad Range Of Ret Fusion-Positive Tumors

* BLUEPRINT MEDICINES ANNOUNCES DATA PRESENTATIONS AT ASCO20 HIGHLIGHTING DEEP, DURABLE CLINICAL ACTIVITY AND WELL-TOLERATED SAFETY PROFILE OF PRALSETINIB ACROSS BROAD RANGE OF RET FUSION-POSITIVE TUMORS

U.S. FDA declines to approve Blueprint's therapy for type of stomach cancer

The U.S. Food and Drug Administration declined to approve Blueprint Medicines Corp's therapy for previously treated patients with a type of cancer that affects the stomach and small intestine, the drugmaker said on Friday.

BRIEF-Blueprint Medicines Receives Complete Response Letter From FDA For Avapritinib NDA For The Treatment Of Fourth-Line Gastrointestinal Stromal Tumor

* BLUEPRINT MEDICINES RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR AVAPRITINIB NEW DRUG APPLICATION FOR THE TREATMENT OF FOURTH-LINE GASTROINTESTINAL STROMAL TUMOR

U.S. FDA declines to approve Blueprint's therapy for type of stomach cancer

The U.S. Food and Drug Administration declined to approve Blueprint Medicines Corp's therapy for previously treated patients with a type of cancer that affects the stomach and small intestine, the drugmaker said on Friday.

BRIEF-Blueprint Medicines Reports Q1 Loss Per Share $2.11

* BLUEPRINT MEDICINES REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS

BRIEF-Blueprint Medicines Announces Top-Line Results From Phase 3 Voyager Trial Of Avapritinib

* BLUEPRINT MEDICINES ANNOUNCES TOP-LINE RESULTS FROM PHASE 3 VOYAGER TRIAL OF AVAPRITINIB VERSUS REGORAFENIB IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR

BRIEF-Blueprint Medicines Announces Achievement Of Key Portfolio Milestones

* BLUEPRINT MEDICINES ANNOUNCES THE ACHIEVEMENT OF KEY PORTFOLIO MILESTONES

BRIEF-Blueprint Medicines Announces Part 1 Results From Pioneer Trial Showing Broad Activity Of Avapritinib

* BLUEPRINT MEDICINES ANNOUNCES PART 1 RESULTS FROM PIONEER TRIAL SHOWING BROAD ACTIVITY OF AVAPRITINIB ACROSS MEASURES OF MAST CELL BURDEN, CLINICAL OUTCOMES AND QUALITY OF LIFE IN INDOLENT SYSTEMIC MASTOCYTOSIS

BRIEF-Blueprint Medicines Files For Potential Mixed Shelf Offering Size Not Disclosed - SEC Filing

* BLUEPRINT MEDICINES CORP FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING Source text: (http://bit.ly/3bAdufL) Further company coverage:

BRIEF-Blueprint Medicines Reports Q4 Loss Per Share Of $1.35

* BLUEPRINT MEDICINES REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

FDA approves Blueprint's stomach cancer therapy priced at $32,000 per month

The U.S. Food and Drug Administration approved Blueprint Medicines Corp's oral therapy to treat a rare form of cancer that affects the stomach and small intestine, the agency said on Thursday.

REFILE-BRIEF-Blueprint Medicines Expects Decision From European Commission On PDGFRA D842V GIST Indication In Q3 2020

* BLUEPRINT MEDICINES - CONTINUES TO PURSUE CONDITIONAL MARKETING AUTHORIZATION FOR AVAPRITINIB FOR PDGFRA D842V MUTANT GIST IN EU

CORRECTED-BRIEF-Blueprint Medicines Receives FDA Approval For Ayvakit For Treatment Of Rare Stomach Cancer - FDA Website

* BLUEPRINT MEDICINES CORP RECEIVES FDA APPROVAL FOR AYVAKIT FOR TREATMENT OF RARE STOMACH CANCER - FDA WEBSITE Source text : (http://bit.ly/36FFxb1) Further company coverage:

U.S. FDA approves Blueprint's therapy for rare type of stomach cancer

The U.S. Food and Drug Administration approved Blueprint Medicines Corp's drug to treat a rare cancer that affects the stomach and small intestine, the agency said on Thursday.

BRIEF-Blueprint Medicines - Entered 7th Amendment To Collaboration & License Agreement, As Amended, With Roche

* BLUEPRINT MEDICINES - ON DEC 17, ENTERED 7TH AMENDMENT TO COLLABORATION & LICENSE AGREEMENT, AS AMENDED, WITH ROCHE

Loxo Oncology's targeted RET drug shows promise in early trial

An experimental Loxo Oncology Inc drug that targets cancers with mistakes in the RET gene led to tumor shrinkage in nearly 70 percent of patients regardless of where their cancer originated, according to preliminary data from a small study released on Wednesday.

BRIEF-Blueprint Medicines Q1 Loss Per Share $1.29

* BLUEPRINT MEDICINES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up